|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.10 TWD | +1.29% |
|
+3.96% | -7.08% |
| Market Cap | 6.63B 207M 181M 167M 155M 294M 19.72B 298M 2B 777M 9.68B 776M 759M 33.56B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 7.74B 242M 212M 195M 181M 343M 23.04B 348M 2.33B 908M 11.31B 907M 887M 39.21B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
80.27% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | +1.29% | ||
| 1 week | +3.96% | ||
| Current month | +2.23% | ||
| 1 month | +3.57% | ||
| 3 months | -0.90% | ||
| 6 months | -5.49% | ||
| Current year | -7.08% |
| 1 week | 52.6 |  | 56.7 |
| 1 month | 50.3 | | 56.7 |
| Current year | 50 | | 62.5 |
| 1 year | 50 | | 72 |
| 3 years | 49.5 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 1995-12-31 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 2003-04-13 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Ting Kai Wu
BRD | Director/Board Member | 88 | 2010-05-10 |
Charles Lin
BRD | Director/Board Member | - | 2016-06-27 |
Cheng Yue Cheng
CHM | Chairman | - | 1995-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.29% | +3.96% | -18.85% | -39.18% | 205M | |
| -1.14% | -2.43% | +53.72% | +159.07% | 1,082B | |
| -1.41% | +0.32% | +66.23% | +60.48% | 633B | |
| -2.42% | +0.18% | +34.59% | +85.62% | 461B | |
| -0.26% | +0.53% | +31.00% | +25.82% | 338B | |
| -2.46% | -1.38% | +36.42% | +36.52% | 299B | |
| -2.20% | -0.87% | +27.50% | +42.69% | 291B | |
| -1.77% | +1.97% | -28.85% | -40.66% | 222B | |
| -2.06% | +1.63% | +22.87% | +64.34% | 202B | |
| -1.26% | +2.60% | +15.98% | +70.00% | 163B | |
| Average | -1.37% | +0.78% | +24.06% | +46.47% | 369.26B | |
| Weighted average by Cap. | -1.55% | -0.22% | +39.61% | +80.56% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 148M 129M 119M 111M 210M 14.08B 213M 1.43B 555M 6.91B 554M 542M 23.96B | 4.85B 151M 133M 122M 113M 215M 14.44B 218M 1.46B 569M 7.09B 568M 556M 24.57B |
| Net income | 157M 4.91M 4.3M 3.96M 3.67M 6.98M 468M 7.07M 47.38M 18.44M 230M 18.43M 18.02M 797M | 441M 13.76M 12.05M 11.1M 10.3M 19.57M 1.31B 19.83M 133M 51.72M 644M 51.68M 50.55M 2.23B |
| Net Debt | 1.2B 37.31M 32.68M 30.1M 27.94M 53.05M 3.56B 53.77M 360M 140M 1.75B 140M 137M 6.06B | 1.12B 34.8M 30.48M 28.07M 26.06M 49.48M 3.32B 50.15M 336M 131M 1.63B 131M 128M 5.65B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-06 | NT$55.10 | +1.29% | 2,015,316 |
| 26-07-03 | NT$54.40 | +1.68% | 1,172,456 |
| 26-07-02 | NT$53.50 | -0.37% | 533,076 |
| 26-07-01 | NT$53.70 | -0.37% | 1,127,703 |
| 26-06-30 | NT$53.90 | +1.70% | 997,622 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
